StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.47−0.25 (-3.24%)

Close on Nov 20, 2026Market cap $1.23BP/E –Yield –

Novavax gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Novavax's gross profit for the twelve months ending Jun 30, 2026 was $325.26M, down 65.8% year over year. For fiscal 2025 it was $1.05B, up 119.1% from the year before. The highest annual figure on record is $1.15B in fiscal 2021.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.05B+119.1%
FY2024Dec 31, 2024$479.42M-25.1%
FY2023Dec 31, 2023$639.94M-40.7%
FY2022Dec 31, 2022$1.08B-5.8%
FY2021Dec 31, 2021$1.15B+141.0%
FY2020Dec 31, 2020$475.60M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$42.45M-81.0%
Q1 FY2026Mar 31, 2026$108.82M-83.3%
Q4 FY2025Dec 31, 2025$125.04M+142.1%
Q3 FY2025Sep 30, 2025$48.95M+104.9%
Q2 FY2025Jun 30, 2025$223.92M-39.4%
Q1 FY2025Mar 31, 2025$652.54M+1783.4%
Q4 FY2024Dec 31, 2024$51.64M-62.1%
Q3 FY2024Sep 30, 2024$23.89M-72.9%
Q2 FY2024Jun 30, 2024$369.24M+0.2%
Q1 FY2024Mar 31, 2024$34.65M-26.1%
Q4 FY2023Dec 31, 2023$136.37M-22.4%
Q3 FY2023Sep 30, 2023$88.06M-70.6%
Q2 FY2023Jun 30, 2023$368.65M–
Q1 FY2023Mar 31, 2023$46.87M-93.2%
Q4 FY2022Dec 31, 2022$175.63M-21.0%
Q3 FY2022Sep 30, 2022$299.98M+67.7%
Q2 FY2022Jun 30, 2022-$85.15M-128.6%
Q1 FY2022Mar 31, 2022$688.77M+54.0%
Q4 FY2021Dec 31, 2021$222.20M–
Q3 FY2021Sep 30, 2021$178.84M–
Q2 FY2021Jun 30, 2021$298.02M–
Q1 FY2021Mar 31, 2021$447.23M–

More Novavax figures

See a number that looks wrong?